country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-P992473

Copy Link Print Information

TAS266

TAS266 is a tetrameric nanobody agonist targeting DR5. TAS266 selectively induces cancer cell death. TAS266 triggers sustained tumor regression in xenograft models and also elicits immunogenic responses including antibody binding. TAS266 exhibits superior anti-tumor efficacy compared with traditional DR5-targeting strategies. TAS266 can be used in research related to pancreatic cancer and advanced solid tumors.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Stockage:

Please store the product under the recommended conditions in the Certificate of Analysis.

TAS266 Chemical Structure

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- Isotype
- Species Reactivity
- In Vitro
- In Vivo
- Gene ID
- Accession
- Target
- Conjugated
- Reconsititution
- Format
- Application
Chemical Information
Pureté et documentation
Références
Calculators
Help & FAQs
Classifications
Bioz

Activité biologique

Description

Isotype

(VHH-VHH-hFc)-dimer

Species Reactivity

Human

Voir tous les produits spécifiques à Isoform TNF Receptor :

In Vitro

TAS266 is up to 1000-fold more potent than cross-linked DR5 antibody or TRAIL at inducing cell death in cancer cell lines via DR5 activation, with faster downstream caspase activation kinetics^[1].
TAS266 potently induces death in human tumor cell lines, with potency ≥1000-fold greater than cross-linked DR5 antibody LBY135 or TRAIL^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

TAS266 (200 mg/kg; twice weekly) shows no target organ toxicity including hepatotoxicity in cynomolgus monkeys after administration, with its biological activity remaining intact^[2].
TAS266 (single dose; weekly) induces tumor regression in a variety of tumor xenograft models, and its antitumor activity with weekly administration is superior to that of DR5 agonist antibodies in pancreatic cancer and colon cancer xenograft models^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

specific strain not specified^[2]
Dosage:

200 mg/kg
Administration:

twice weekly
Result:

Showed no clinical or histopathologic evidence of target organ toxicity, including negative caspase immunohistochemistry of liver tissue.
Maintained bioactivity despite presence of preexisting or treatment-emergent TAS266-binding IgG antibodies in some animals.

Animal Model:

specific strain not specified (immunocompromised)^[2]
Dosage:

Single dose; weekly dose
Administration:

single dose; weekly
Result:

Elicited tumor regressions in multiple human tumor xenograft models.
Exhibited superior anti-tumor activity compared with a DR5 agonist antibody in patient-derived pancreatic and colon xenograft models.

Gene ID

8795 [NCBI]

Accession

O14763

Target

TNFRSF10B/TRAILR2/CD262

Conjugated

Unconjugated

Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.

Format

Product Image

Application

ELISA, FACS, Functional assay

Chemical Information

Formulation

Please refer to the lot-specific COA for specific buffer information.
Stockage

Please store the product under the recommended conditions in the Certificate of Analysis.

Pureté et documentation

Inhibitory Antibodies User Guide (603 KB)

Références

[1]. Huet H, et al. TAS266, a novel tetrameric nanobody agonist targeting death receptor 5 (DR5), elicits superior antitumor efficacy than conventional DR5-targeted approaches[J]. Cancer Research, 2012, 72(8_Supplement): 3853-3853.

[2]. Papadopoulos KP, et al. Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic Nanobody® targeting the DR5 receptor. Cancer Chemother Pharmacol. 2015;75(5):887-895. [Content Brief]

Calculators

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

MOQ

Minimum order quantity

100 mg

Obtenir un devis En stock

Other size

Obtenir un devis

Amount: USD 0.00

Activité biologique
- Description
- Isotype
- Species Reactivity
- In Vitro
- In Vivo
- Gene ID
- Accession
- Target
- Conjugated
- Reconsititution
- Format
- Application
Chemical Information
Pureté et documentation
Références

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

TAS266

Cytotoxicity LDH Assay Kit

DPBS Buffer (1×)

PBS Buffer (1×)

Voir tous les produits spécifiques à Isoform TNF Receptor

Activité biologique

Chemical Information

Pureté et documentation

Références

Calculators

Help & FAQs

TAS266 Related Classifications

HY-P992473 Related Classifications